Inspection Record

Sentara Enterprises — FDA 483 Findings

US FDAInspected 2023-07-14Published 2024-03-20 5 findingsAseptic processing and sterility assuranceOther quality system

Inspectors Tekalign WondimuThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Personnel were observed conducting aseptic manipulations where the movement of "first air" in the ISO 5 area is blocked or disrupted.

2Aseptic processing and sterility assurance

Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.

3Other quality system

Lack of disinfection of supplies at each transition from areas of lower quality air to areas of higher quality air.

4Aseptic processing and sterility assurance

Personnel performed aseptic manipulations with exposed hair or skin.

5Aseptic processing and sterility assurance

Smoke studies were inadequately performed under dynamic conditions.

About this record

Extracted automatically from the document US FDA published on 2024-03-20. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Sentara Enterprises company profile — full history US FDA documents, 2024 Go to Findings search